Welcome to our dedicated page for HEMAB THERAPEUTICS HOLDINGS SEC filings (Ticker: COAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HEMAB THERAPEUTICS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HEMAB THERAPEUTICS HOLDINGS's regulatory disclosures and financial reporting.
Hemab Therapeutics Holdings, Inc. disclosed that investment vehicles associated with RA Capital made open-market purchases of its Common Stock. On May 19, an RA Capital-related entity bought 3,802 shares at a weighted average price of $24.97 per share, and on May 20 another purchase of 996 shares was made at a weighted average price of $24.94 per share. Following these transactions, RA Capital-affiliated entities indirectly held 6,376,968 shares of Hemab Therapeutics Common Stock. The filing notes that shares are held directly by RA Capital Healthcare Fund, L.P. and RA Capital Nexus funds, and that the Adviser, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Hemab Therapeutics Holdings, Inc. reports higher first-quarter 2026 operating losses as it invests heavily in its coagulation disorder pipeline. Net loss was $22.7 million for the three months ended March 31, 2026, compared with $15.3 million a year earlier, driven mainly by increased research and development spending.
Research and development expenses rose to $19.5 million and general and administrative costs to $4.2 million as the company advanced its lead antibodies sutacimig and HMB‑002 and expanded headcount and professional services. Cash, cash equivalents and marketable securities totaled $163.5 million as of March 31, 2026.
After quarter end, Hemab completed an IPO with net proceeds of approximately $317.2 million, and management believes this, together with existing cash and investments, can fund operations into 2029. The company remains a clinical‑stage biotech with no product revenue and a cumulative deficit of $204.5 million, reflecting its early‑stage, growth‑focused profile.
Hemab Therapeutics Holdings, Inc. furnished its first quarter 2026 results and recent milestones. The company completed an upsized IPO in May 2026, selling 19,262,500 shares at $18.00 per share and raising gross proceeds of $346.7 million, and its stock now trades on the Nasdaq Global Select Market under the symbol COAG.
For the quarter ended March 31, 2026, Hemab reported a net loss of $22.7 million, driven mainly by $19.5 million in research and development and $4.2 million in general and administrative expenses. Cash and cash equivalents were $49.9 million and marketable securities were $113.7 million as of March 31, 2026, supporting its clinical-stage pipeline, including sutacimig and HMB‑002 for rare coagulation disorders.
Hemab Therapeutics Holdings, Inc. reported an insider open-market purchase by entities managed by RA Capital Management. An RA Capital-affiliated fund bought 6,387 shares of common stock at a weighted average price of $24.90 per share, with trade prices ranging from $24.70 to $25.00. Following this transaction, the fund indirectly holds 6,372,170 shares of Hemab Therapeutics common stock, while related Nexus funds report indirect holdings of 354,938 and 1,009,052 shares. RA Capital Management, its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Hemab Therapeutics Holdings, Inc. reported initial insider holdings for major shareholder AI DEN-MAB LLC. AI DEN-MAB LLC directly holds 4,876,344 shares of Common Stock as of May 4, 2026, establishing it as a significant owner.
According to the disclosure, these securities may be deemed beneficially owned by AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik through their control relationships. Each of these parties disclaims beneficial ownership beyond its or his pecuniary interest.
Hemab Therapeutics Holdings, Inc. reporting persons led by RA Capital Management, L.P. report beneficial ownership of 7,729,773 shares of common stock, equal to 16.6% of the class. The filing states 46,705,410 shares outstanding as of May 4, 2026.
The filing discloses that the 7,729,773 figure reflects shared voting and shared dispositive power held by RA Capital and named individuals, and that 6,365,783 of those shares are held directly by RA Capital Healthcare Fund, L.P. The filing also explains delegation of voting and disposition authority to RA Capital and contains disclaimers of beneficial ownership by certain funds and the reporting persons.
Hemab Therapeutics Holdings, Inc. reported multiple open-market purchases of its Common Stock by entities associated with RA Capital. Over May 7–11, RA Capital–managed funds bought a total of 51,258 shares at weighted average prices generally between about $23.78 and $25.00 per share, across several transaction ranges noted in the footnotes. Following these purchases, RA Capital–related entities reported indirect ownership of 6,365,783 shares of Hemab common stock. Shares are held directly by RA Capital Healthcare Fund LP, RA Capital Nexus II Fund LP, and RA Capital Nexus IV Fund LP, while RA Capital Management, L.P., its general partner, and principals Peter Kolchinsky and Rajeev Shah act as investment managers and disclaim beneficial ownership except to the extent of their pecuniary interests.
Access Industries affiliates report a significant stake in Hemab Therapeutics Holdings, Inc. AI DEN-MAB LLC and related entities disclose beneficial ownership of 4,876,344 shares of common stock, representing 10.4% of Hemab’s outstanding shares following its initial public offering.
AI DEN-MAB built the position through preferred investments in Hemab ApS that later converted into 3,776,344 common shares after a 22-for-one stock split, plus a purchase of 1,100,000 shares in the IPO at $18.00 per share. The group describes the investment as made in the ordinary course of business but may buy or sell more shares over time.
AI DEN-MAB is subject to a 180-day lock-up from April 30, 2026, limiting sales or hedging of its Hemab holdings. It also holds registration rights under an Investors' Rights Agreement, including demand, shelf and piggyback rights once the IPO lock-up period and related conditions are met.
Hemab Therapeutics Holdings, Inc. reported that Laura Tadvalkar, Ph.D. has resigned from its board of directors, effective May 8, 2026. The company states that her resignation is not related to any disagreement with Hemab on operations, policies, or practices.
Hemab Therapeutics Holdings, Inc. passive ownership disclosure: Deep Track-related entities reported beneficial ownership positions in Hemab common stock totaling up to 3,600,996 shares (8.15%) as of May 8, 2026. The filing states the ownership percentages use 44,192,910 shares outstanding as of May 1, 2026.
The Schedule 13G is a joint filing by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; Deep Track Special Opportunities Fund, LP; and David Kroin, identifying shared voting and dispositive power over reported holdings.